204 related articles for article (PubMed ID: 2763404)
1. Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin.
Brenner DW; Yore LM; Schellhammer PF
Urology; 1989 Aug; 34(2):93-5. PubMed ID: 2763404
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
3. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
5. [Intravesical Calmette-Guérin bacillus therapy of bladder tumors].
Uchida T; Muruyama M; Igarashi M; Kobayashi K; Mashimo S; Ishibashi A; Koshiba K; Shibuya M
Nihon Hinyokika Gakkai Zasshi; 1987 Dec; 78(12):2087-97. PubMed ID: 3451983
[No Abstract] [Full Text] [Related]
6. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
7. BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder.
Akaza H
Eur Urol; 1995; 27 Suppl 1():9-12. PubMed ID: 7750530
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
10. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guerin immunotherapy.
Lamm DL
J Urol; 1987 Aug; 138(2):391-2. PubMed ID: 3599262
[No Abstract] [Full Text] [Related]
12. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
13. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
14. Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry.
Staiano-Coico L; Huffman J; Wolf R; Pinsky CM; Herr HW; Whitmore WF; Oettgen HF; Darzynkiewicz Z; Melamed MR
J Urol; 1985 May; 133(5):786-8. PubMed ID: 3989917
[TBL] [Abstract][Full Text] [Related]
15. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer.
Bassi P; Milani C; Meneghini A; Garbeglio A; Aragona F; Zattoni F; Dalla Palma P; Rebuffi A; Pagano F
Urology; 1992 Aug; 40(2):175-9. PubMed ID: 1502759
[TBL] [Abstract][Full Text] [Related]
17. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
[TBL] [Abstract][Full Text] [Related]
18. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
20. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
